Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (409)	10/8/2003 11:51:47 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

PCYC and TTP were among a group of stocks that came up on today's scan for stocks on UPTRENDS. Message 19384580 Bernard

To: Jibacoa who wrote (409)	10/9/2003 11:51:35 AM
From: JMarcus	Respond to of 3722

A quick OT response on your AVGN comment: <<Although Parkinson's disease is pretty prevalent,I don't know how well this invasive, "pro-drug" approach will be largely accepted.>> The CEO clearly views Avigen as a platform company. His short-term goal isn't sales, but proof of principle. If the AAV vector's viability for gene therapy can be proven, through clinical trials in humans, that proof of principle would be a binary event for Avigen. Partnership deals for new indications would then start lining up at the front door -- leastwise that's the business model he has in mind. Bayer has already given Avigen a bucket-load of cash, so they aren't under pressure to achieve near-term sales. Marc